10-K: Intensity Therapeutics Reports 2024 Financial Results, Highlights Clinical Progress

Intensity Therapeutics files its 10-K, reporting on its financial performance for 2024 and outlining key clinical trial advancements.

Summary

• Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, has filed its Form 10-K for the year ended December 31, 2024.
• The company is focused on developing localized cancer reduction treatments leading to anti-cancer immune activation using its DfuseRx SM discovery platform.
• Their lead product candidate, INT230-6, is undergoing clinical trials for various cancer types.
• The INVINCIBLE-3 Study, a Phase 3 trial for soft tissue sarcoma, is currently enrolling patients across eight countries with an expected completion in the first half of 2026.
• The INVINCIBLE-4 Study, a Phase 2 trial for triple-negative breast cancer, is also enrolling patients with an expected completion by the end of the first quarter of 2026.
• The company reported a net loss of $16.3 million for 2024, compared to a net loss of $10.5 million in 2023.
• As of December 31, 2024, the company's cash and cash equivalents were $2.6 million.
• The company states that it will need to raise additional funding to continue operations.
• The report from the company's independent registered public accounting firm contains a statement with respect to substantial doubt as to the company's ability to continue as a going concern.
• As of March 1, 2025, the company had sixteen employees and contractors.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's clinical progress, the financial situation is concerning due to increasing losses and a going concern warning. The need for additional funding adds uncertainty.

Positives

• INT230-6 has shown promising results in early-stage breast cancer tumors, with some patients experiencing greater than 95% necrosis of the tumor.
• INT230-6 has a favorable safety profile.
• INT230-6 demonstrated an increase in CD4 T-cells and NK cells within tumors and gene expression profiling revealed a treatment effect of up-regulation of immune pathways expressed by T-cell activation, lymphocyte activation and inflammatory responses.
• INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients blood compared to baseline that was also much larger than a control saline injection.
• The FDA granted orphan drug designation for the treatment of soft tissue sarcoma to the three active moieties comprising INT230-6: cisplatin, vinblastine sulfate, and the diffusion enhancer SHAO.

Negatives

• The company has incurred net losses in each year since its inception, and had an accumulated deficit of $66.8 million as of December 31, 2024.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• The company will need to raise substantial additional funding or it will be forced to delay, reduce or eliminate some of its product-development programs or commercialization efforts.

Risks

• The company's future success is heavily dependent on the success of its new intratumoral technology, which requires additional development and may never receive regulatory approval or be successfully commercialized.
• The company has limited experience conducting cancer clinical trials, and is subject to risks and challenges that may prevent or delay the completion of its upcoming or on-going clinical trials.
• The company's prospects for obtaining additional financing are uncertain.
• The company has yet to obtain regulatory approval from the FDA, and therefore is not currently permitted to market products made using its technology in the United States.
• Delays in FDA approval could be costly to the company and prevent it from commercializing its product candidates effectively.
• Even if product candidates using the company's technology obtain approval, the company will be subject to additional ongoing regulatory obligations and oversight.
• The company will rely on third parties to conduct preclinical research and any clinical trials.
• Third-party payors may not reimburse for the use of the company's product candidates, or such reimbursement may be inadequate.
• The company is dependent on third parties to manufacture components of the final drug products made using its technology.
• The company purchases components for its product candidates from third parties, some of which may be sole-source suppliers.
• The company has not entered into long term manufacturing and supply agreements with any producers.
• The company has limited experience and may not be successful in commercializing products that use its technology.
• The company's plan to use collaborative arrangements with third parties to help finance and to market and sell products using its technology may not be successful.
• The company will be dependent on healthcare professionals' efforts to learn about its product candidates.
• Rapid technological developments in treatment methods for cancer and competition with other forms of cancer treatments could affect the company's ability to achieve meaningful revenues or profit.
• The company's success depends in part on its ability to obtain patents, maintain trade secret protection, operate without infringing on the proprietary rights of third parties, and commercialize its technology prior to the expiration of its patent protection.
• The company may be unable to protect its intellectual property rights because of its limited resources.
• The company may be the subject of product liability claims or product recalls.
• The market price of the company's Common Stock may be highly volatile, and investors could lose all or part of their investment.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the next several years as it continues to fund its INVINCIBLE-3 and INVINCIBLE-4 clinical studies, incur manufacturing costs, seek regulatory approvals, hire additional personnel, expand its operational, financial, and management systems, invest in intellectual property protection, and establish a sales, marketing, medical affairs, and distribution infrastructure.

Management Comments

• The company intends to apply its deep understanding of its novel drug delivery technology to create a range of new direct killing and immune-activating products candidates while focusing on its lead clinical programs.
• The company's objective is for patients to overcome their cancer without harm, to live a long life with high quality and to eliminate the fear of disease recurrence or the therapy itself.
• The company maintains a culture of high integrity that embraces the patient and their caregivers, believing that taking care of the patient will benefit all stakeholders.

Industry Context

The announcement highlights the ongoing competition in the biopharmaceutical industry, particularly in the development of immune-oncology therapies for cancer treatment. It also acknowledges the challenges in developing effective cancer treatments with less toxicity and the need for improved drug delivery methods.

Comparison to Industry Standards

• The document compares the company's Phase 1/2 basket study survival data in soft tissue sarcoma (STS) to overall survival data generated from three published clinical Phase 1/2 basket trials in sarcoma.
• The three studies used for comparison were: Jones Cancer Chemother Pharmacol (2011), Cassier et. al., Annals of Oncology 25: 1222 1228, 2014, and Subbiah et. al., Scientific Reports | 6:35448 2016.
• The document notes that the median overall survival (mOS) from the Jones, Cassier and Subbiah studies are similar.
• The document also compares the company's expected Phase 3 survival for INT230-6 to the survival curves from five recent Phase 3 studies using now approved SOC drugs for sarcoma, including trabectadin, eribulin, and pazopanib.

Related Party Transactions

• In 2023, a minority stockholder was engaged as a consultant to serve as the company's chief medical officer.
• The company sublet a portion of its lease in Westport Lease to a minority stockholder, and recognized sublease income of approximately $23,000 for the year ended December 31, 2023.
• As of December 31, 2023, the company held a $36,000 deposit related to a service agreement with a minority stockholder.
• In October 2023, the company issued 80,000 warrants for consulting services to be rendered by two shareholders.
• In April 2024, the company entered into a non-material agreement with a service organization controlled by a board member.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial situation and potential need to reduce operations.
• Patients may benefit from the company's clinical progress, but face uncertainty regarding the availability of INT230-6 if the company cannot secure additional funding.
• Suppliers and creditors face increased risk of non-payment due to the company's financial situation.

Next Steps

• Continue enrolling patients in the INVINCIBLE-3 Study and INVINCIBLE-4 Study.
• Execute the agreed-upon CMC plan with the FDA for Phase 3 and product registration.
• Seek additional funding to support ongoing operations and clinical trials.

Key Dates